Olaparib

Phase 1/2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pulmonary Arterial Hypertension

Conditions

Pulmonary Arterial Hypertension

Trial Timeline

Nov 20, 2019 → Oct 31, 2024

NCT ID

NCT03782818

About Olaparib

Olaparib is a phase 1/2 stage product being developed by AstraZeneca for Pulmonary Arterial Hypertension. The current trial status is terminated. This product is registered under clinical trial identifier NCT03782818. Target conditions include Pulmonary Arterial Hypertension.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03063710	Pre-clinical	Completed	—	—	PSR Ovarian Cancer With a BRCA Mutation
NCT05501548	Phase 2	Terminated	Jun 30, 2023	Oct 14, 2024	Prostate Cancer
NCT04951492	Phase 2	Terminated	Nov 9, 2022	Oct 15, 2023	Castration-Resistant Prostate Carcinoma
NCT05482074	Phase 2	Withdrawn	Oct 4, 2022	May 1, 2027	Recurrent Metastatic Melanoma
NCT05262608	Phase 2	UNKNOWN	Dec 7, 2021	Apr 26, 2024	Prostate Cancer
NCT04884360	Phase 3	Active	May 31, 2021	Jul 27, 2027	Ovarian Cancer
NCT04515836	Phase 2	Recruiting	Feb 19, 2021	Apr 15, 2028	Mesothelioma
NCT04532645	Pre-clinical	Completed	Jan 7, 2021	Sep 27, 2024	Ovary Cancer
NCT04421963	Phase 3	Active	Aug 4, 2020	Apr 6, 2027	Ovarian Cancer
NCT04330040	Approved	Completed	May 25, 2020	Sep 30, 2022	Ovarian Cancer
NCT04236414	Phase 1	Completed	Jan 14, 2020	Feb 4, 2025	Solid Tumours
NCT03782818	Phase 1/2	Terminated	Nov 20, 2019	Oct 31, 2024	Pulmonary Arterial Hypertension
NCT03829345	Phase 2	UNKNOWN	Jul 2, 2019	Feb 14, 2022	Oesophageal Cancer
NCT03786796	Phase 2	Recruiting	Jun 3, 2019	Mar 1, 2028	Renal Cell Carcinoma
NCT03955640	Phase 1	Terminated	May 20, 2019	Aug 26, 2021	Metastatic Malignant Neoplasm in the Chest Wall
NCT03742895	Phase 2	Active	Dec 12, 2018	Jun 30, 2026	Advanced Solid Neoplasms
NCT04152941	Pre-clinical	Completed	Oct 11, 2018	Feb 11, 2020	Relapsed Ovarian Cancers Patients
NCT03570476	Phase 2	Terminated	Sep 11, 2018	Jul 3, 2019	Prostate Adenocarcinoma Without Neuroendocrine Differentiation
NCT03470805	Phase 2	Completed	Jun 21, 2018	Jul 27, 2022	Ovarian Cancer
NCT03448718	Phase 2	Completed	Apr 17, 2018	Oct 15, 2021	Metastatic Urothelial Cancer

Competing Products

20 competing products in Pulmonary Arterial Hypertension

See all competitors

Product	Company	Stage	Hype Score
AP01	Avalyn Pharmaceuticals	Phase 2	44
macitentan 10 mg	BML, Inc.	Phase 3	76
tadalafil + tadalafil	Eli Lilly	Phase 3	77
CS1 Administration	Cereno Scientific	Phase 2	47
CS1	Cereno Scientific	Pre-clinical	18
TX000045- Dose A + TX000045- Dose B + Placebo	Tectonic Therapeutic	Phase 2	44
Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks	Keros Therapeutics	Phase 2	44
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 1	25
LTI-03 + Placebo	Rein Therapeutics	Phase 2	44
Satralizumab (Genetical Recombination)	Chugai Pharmaceutical	Phase 2	52
DS-1040b + Placebo + Enoxaparin	Daiichi Sankyo	Phase 1/2	41
DS-9231 + Placebo	Daiichi Sankyo	Phase 2	52
Regadenoson	Astellas Pharma	Pre-clinical	23
Reldesemtiv + Placebo	Astellas Pharma	Phase 2	52
Monteplase	Eisai	Approved	85
lysozyme 90 mg + Placebo	Eisai	Approved	85
Prednisolone + Voriconazole	Cipla	Phase 2/3	65
Drotrecogin Alfa (Activated) + Enoxaparin + Placebo + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated) + Drotrecogin Alfa (Activated)	Eli Lilly	Phase 2	52
tadalafil and ambrisentan upfront combination therapy	Eli Lilly	Approved	85

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved